Palazestrant clinical trials
Also written OP-1250.
How each study uses palazestrant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the palazestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Olema Pharmaceuticals, Inc. (4)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses palazestrant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruitingPhase 3Olema Pharmaceuticals, Inc.NCT07085767Written as Palazestrant
- OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerActive, not recruitingPhase 3Olema Pharmaceuticals, Inc.NCT06016738Written as Palazestrant
- A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerCompletedPhase 1/2Olema Pharmaceuticals, Inc.NCT04505826Written as OP-1250
- A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer PatientsActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05266105Written as Palazestrant
Given beside what is tested · 2 — palazestrant is usual care or a partner of the new treatment
- Phase 1 Study of OP-3136 in Advanced or Metastatic Solid TumorsRecruitingPhase 1Olema Pharmaceuticals, Inc.NCT06784193Written as Palazestrant
- Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingPhase 1Olema Pharmaceuticals, Inc.NCT05508906Written as Palazestrant
Codes
What other systems call palazestrant · ClinicalTrials.gg INT018272
- UNII (FDA) VU35KM56Q4PALAZESTRANTOne source FDA
- NCI Thesaurus C176877PalazestrantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | VU35KM56Q4 | PALAZESTRANT | One source FDA |
| NCI Thesaurus | C176877 | Palazestrant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.